Cellectis SA (CLLS)
3.37
+0.14
(+4.33%)
USD |
NASDAQ |
Mar 25, 16:00
Cellectis Cash from Investing (Quarterly) : 22.57M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| DBV Technologies SA | -0.2404M |
| EDAP TMS SA | -1.131M |
| Akari Therapeutics Plc | 0.00 |
| Biodexa Pharmaceuticals Plc | -- |
| Autolus Therapeutics Plc | 35.49M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.47M |
| Cash from Financing (Quarterly) | -4.029M |
| Free Cash Flow | -43.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1093 |
| Free Cash Flow to Equity (Quarterly) | -11.64M |
| Free Cash Flow to Firm (Quarterly) | -9.088M |
| Free Cash Flow Yield | -12.88% |